COMPANY
Clinical Phase 1
Keywords: antibody monoclonal antibody oncology DCSZ11 DCBY02
Location: Waltham, MA · source · Oct 14, 2026
Profile checked Oct 10, 2026
Timeline
- Trial start Phase 1: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors source ↗
- Trial start Phase 1: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors source ↗
Upcoming milestones
- 2026-12 (ESTIMATED) · Phase 1 · DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors · NCT05785754
Estimated primary completion per ClinicalTrials.gov. Dates move.
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT05785754 | DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Jun 28, 2023 | 2026-12 (estimated) |
| NCT05496595 | DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Terminated | Oct 26, 2022 | Feb 5, 2024 (actual) |
